

From: [REDACTED] (SANTE)
Sent: mardi 27 octobre 2020 10:11
To: GALLINA Sandra (SANTE); [REDACTED] (SANTE); [REDACTED]
[REDACTED] (SANTE); [REDACTED] (SANTE);
(SANTE); [REDACTED] (SANTE); [REDACTED] an (SANTE)
Cc: [REDACTED] (SANTE); [REDACTED] ia (SANTE);
[REDACTED] (SANTE)
Subject: Summary of the meeting with Sanofi, 26 October, 12:00 – 12:45 pm, [REDACTED]

Dear All,

Please find below a short summary of yesterday's meeting for your perusal – grateful for any comments or suggestions.

With my best regards,

Sanofi – EC meeting, 26 October, 12:00 – 12:45 pm, via WebEx

Participants:

_____ e Sanofi Executive

Committee

Sanofi

Sandra Gallina (EC)

(EC)
(EC)
C)
(EC)
(EC)
(EC)
(EC)

- After a round of introductions, Sanofi set out their activities and vision for how Europe should act, captured in the circulated papers produced over the summer: emphasis on multiple technological platforms needed for the vaccine and that Europe organises its production in Europe;
- The European Commission (EC) noted previous discussions and commended Sanofi for their European ethos;
- [REDACTED]
- The EC explained that the situation is complex (e.g. participation from other investors needed at EU level, [REDACTED]) and political buy-in (political participation from others) is of

utmost importance; there were limits (including financial) also to the mirroring of BARDA;

- [REDACTED]
- [REDACTED]
- EC indicated that they would consider what they could do to address these concerns, particularly in light of BARDA-type reflections. The EC congratulated Sanofi for their interesting proposal and their willingness to occupy the economic space.

[REDACTED]

[REDACTED]



European Commission

[REDACTED]

[@ec.europa.eu](https://twitter.com/ec_europa)

Follow us on Twitter:

[@EU_Health](https://twitter.com/EU_Health) [@Food_EU](https://twitter.com/Food_EU)